Creabilis raises $20M in Series B funding

Tuesday, October 4, 2011

Creabilis, a clinical stage European biotechnology company, has raised $20 million in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company’s first-in-class treatments, including its lead product CT327 to the end of phase II.

[Read More]

Creabilis expands management team

Thursday, August 18, 2011

Creabilis has expanded its senior management team. Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president of chemistry manufacturing and controls.

[Read More]